Coagulation factor inhibitors in COVID-19: From SARS-CoV-2 vaccination to infection.
Jeremy W JacobsBrian D AdkinsShannon C WalkerGarrett S BoothAllison P WheelerPublished in: Research and practice in thrombosis and haemostasis (2022)
The incidence of coagulation factor inhibitors in patients with SARS-CoV-2 vaccination and infection appears similar to the general population. Nonetheless, given the importance of heparin therapy in treating hospital patients, recognition of inhibitors is important.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- ejection fraction
- chronic kidney disease
- coronavirus disease
- newly diagnosed
- healthcare
- prognostic factors
- emergency department
- venous thromboembolism
- risk factors
- patient reported outcomes
- bone marrow
- replacement therapy
- cell therapy
- smoking cessation
- drug induced